Insider Selling: Adlai Nortye (NASDAQ:ANL) CFO Sells $80,754.75 in Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 5,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the transaction, the chief financial officer directly owned 147,757 shares of the company’s stock, valued at $2,105,537.25. This represents a 3.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Monday, August 24th, Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock. The shares were sold at an average price of $13.98, for a total transaction of $83,880.00.

Adlai Nortye Stock Down 3.5%

Shares of ANL opened at $13.82 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The business’s 50 day moving average price is $12.16 and its 200-day moving average price is $11.21. Adlai Nortye Ltd. Sponsored ADR has a 52 week low of $0.88 and a 52 week high of $17.25.

Hedge Funds Weigh In On Adlai Nortye

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Braidwell LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $9,145,000. Boone Capital Management LLC bought a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $2,971,000. Affinity Asset Advisors LLC bought a new stake in shares of Adlai Nortye during the 1st quarter valued at about $1,140,000. ADAR1 Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $816,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $1,302,000. 35.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on ANL. Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. JonesTrading initiated coverage on Adlai Nortye in a report on Thursday, May 14th. They set a “buy” rating and a $22.00 price target for the company. Oppenheimer assumed coverage on Adlai Nortye in a research report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price target for the company. Cantor Fitzgerald started coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $24.25.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.